Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Martin Gleave

Showing results (131-140 of 259) with videos related to

Pageof 26
Sort By:
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 27, 2011
Randomized phase II trial of Custirsen (OGX-011) in combination with docetaxel or mitoxantrone as second-line therapy in patients with metastatic castrate-resistant prostate cancer progressing after first-line docetaxel: CUOG trial P-06cFred Saad, Sebastien Hotte, Scott North, et al.
European Urology|May 20, 2011
New therapies for castration-resistant prostate cancer: efficacy and safetyHimisha Beltran, Tomasz M Beer, Michael A Carducci, et al.
Nucleic Acids Research|May 15, 2020
G3BP1-linked mRNA partitioning supports selective protein synthesis in response to oxidative stressSyam Prakash Somasekharan, Fan Zhang, Neetu Saxena, et al.
Future Oncology (London, England)|July 6, 2026
How enzalutamide affects sex life and how taking a break from treatment affects quality of life: a plain language summary of results from the EMBARK study in people with hormone-sensitive prostate cancer and high-risk biochemical recurrenceStephen J Freedland, Ugo De Giorgi, Antti Rannikko, et al.
Cell Death Discovery|January 12, 2025
Developing novel Lin28 inhibitors by computer aided drug designVictor M Matias-Barrios, Mariia Radaeva, Graciella Rosellinny, et al.
European Urology Focus|July 21, 2017
Targeting Adaptive Pathways in Metastatic Treatment-Resistant Prostate Cancer: Update on the Stand Up 2 Cancer/Prostate Cancer Foundation-Supported West Coast Prostate Cancer Dream TeamRahul Aggarwal, Tomasz M Beer, Martin Gleave, et al.
Nature Communications|December 11, 2025
BPTF regulates androgen receptor activity by enhancing chromatin accessibility and stabilizing the AR-FOXA1 interactionHee-Young Jeon, Sudeep Khadka, Majid Pornour, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 18, 2005
A phase II, pharmacokinetic, and biological correlative study of oblimersen sodium and docetaxel in patients with hormone-refractory prostate cancerAnthony W Tolcher, Kim Chi, John Kuhn, et al.
FASEB Journal : Official Publication of the Federation of American Societies for Experimental Biology|June 28, 2013
Extracellular HSP27 mediates angiogenesis through Toll-like receptor 3Dominique Thuringer, Gaetan Jego, Guillaume Wettstein, et al.
Molecular Endocrinology (Baltimore, Md.)|June 30, 2012
Slug, a unique androgen-regulated transcription factor, coordinates androgen receptor to facilitate castration resistance in prostate cancerKaijie Wu, Crystal Gore, Lin Yang, et al.
Pageof 26

Showing results (131-140 of 259) with videos related to

Sort By:
Pageof 26
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 27, 2011
Randomized phase II trial of Custirsen (OGX-011) in combination with docetaxel or mitoxantrone as second-line therapy in patients with metastatic castrate-resistant prostate cancer progressing after first-line docetaxel: CUOG trial P-06cFred Saad, Sebastien Hotte, Scott North, et al.
European Urology|May 20, 2011
New therapies for castration-resistant prostate cancer: efficacy and safetyHimisha Beltran, Tomasz M Beer, Michael A Carducci, et al.
Nucleic Acids Research|May 15, 2020
G3BP1-linked mRNA partitioning supports selective protein synthesis in response to oxidative stressSyam Prakash Somasekharan, Fan Zhang, Neetu Saxena, et al.
Future Oncology (London, England)|July 6, 2026
How enzalutamide affects sex life and how taking a break from treatment affects quality of life: a plain language summary of results from the EMBARK study in people with hormone-sensitive prostate cancer and high-risk biochemical recurrenceStephen J Freedland, Ugo De Giorgi, Antti Rannikko, et al.
Cell Death Discovery|January 12, 2025
Developing novel Lin28 inhibitors by computer aided drug designVictor M Matias-Barrios, Mariia Radaeva, Graciella Rosellinny, et al.
European Urology Focus|July 21, 2017
Targeting Adaptive Pathways in Metastatic Treatment-Resistant Prostate Cancer: Update on the Stand Up 2 Cancer/Prostate Cancer Foundation-Supported West Coast Prostate Cancer Dream TeamRahul Aggarwal, Tomasz M Beer, Martin Gleave, et al.
Nature Communications|December 11, 2025
BPTF regulates androgen receptor activity by enhancing chromatin accessibility and stabilizing the AR-FOXA1 interactionHee-Young Jeon, Sudeep Khadka, Majid Pornour, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 18, 2005
A phase II, pharmacokinetic, and biological correlative study of oblimersen sodium and docetaxel in patients with hormone-refractory prostate cancerAnthony W Tolcher, Kim Chi, John Kuhn, et al.
FASEB Journal : Official Publication of the Federation of American Societies for Experimental Biology|June 28, 2013
Extracellular HSP27 mediates angiogenesis through Toll-like receptor 3Dominique Thuringer, Gaetan Jego, Guillaume Wettstein, et al.
Molecular Endocrinology (Baltimore, Md.)|June 30, 2012
Slug, a unique androgen-regulated transcription factor, coordinates androgen receptor to facilitate castration resistance in prostate cancerKaijie Wu, Crystal Gore, Lin Yang, et al.
Pageof 26